MIAMI, April 2, 2021 /PRNewswire/ -- eMed™, the
architect behind the first BinaxNOW™ at-home COVID-19 test kit,
announces the non-prescription home use availability of third-party
guided and verified COVID-19 at-home tests for asymptomatic serial
testing and screening, with results accepted by many airlines and
businesses using the Abbott BinaxNOW™ home test and eMed telehealth
services.
"I want to congratulate and thank Robert
Ford, Abbott CEO, for believing in and forging ahead on this
important mission to help democratize healthcare," said eMed
Co-Founder and CEO, Dr. Patrice
Harris. "eMed's third-party verification technology platform
was instrumental in reconfiguring Abbott's professional-use
BinaxNOW test for at-home use, resulting in Abbott receiving its
first FDA EUA approval for at-home testing in December 2020. I'm so proud of how far we have
come in bringing affordable test solutions to all Americans,
including vulnerable populations."
Since receiving EUA approval, eMed, in partnership with Abbott,
has distributed and administered millions of tests to states,
nonprofit organizations, schools, businesses and individuals across
the country.
eMed is actively working with other test manufacturers applying
its eMed technology to home-enable third-party verified results for
other diagnostic tests such as influenza, drug testing and sexually
transmitted infections, among other conditions.
eMed tests are always virtually guided by an eMed Certified
Guide, who monitors the test and provides third-party validation of
the result. eMed reports results to the appropriate public health
authorities, providing critical data for population health
management.
About eMed
eMed (www.eMed.com) is a digital-point-of-care health company
democratizing healthcare with a digital platform that provides
fast, easy and affordable at-home healthcare testing, supervised
and guided online by eMed Certified Guides. We embrace quantitative
medicine to deliver prescribed tests and treatments directly to
patients, driving better and more cost-effective health
outcomes.
- This product has not been FDA cleared or approved; but has been
authorized by FDA under an EUA;
- This product has been authorized only for the detection of
proteins from SARS-CoV-2, not for any other viruses or pathogens;
and,
- This product is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked sooner.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/emed-announces-over-the-counter-approval-for-abbotts-rapid-at-home-testing-with-verified-results-301261494.html
SOURCE eMed